Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 39.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 122,306 shares of the company’s stock after selling 80,904 shares during the period. Envestnet Asset Management Inc. owned 0.12% of Neurocrine Biosciences worth $13,527,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Huntington National Bank boosted its stake in Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Neurocrine Biosciences during the 1st quarter valued at about $34,000. GeoWealth Management LLC raised its position in shares of Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock worth $35,000 after buying an additional 102 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 116.9% in the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after acquiring an additional 214 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Neurocrine Biosciences by 404.9% in the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company’s stock worth $45,000 after acquiring an additional 328 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $132.02 on Friday. The firm has a market cap of $13.07 billion, a PE ratio of 44.75, a P/E/G ratio of 1.37 and a beta of 0.24. The firm’s 50 day moving average price is $125.51 and its two-hundred day moving average price is $121.51. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.20 EPS. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. UBS Group upped their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, July 9th. Needham & Company LLC upped their price target on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $145.00 price target on shares of Neurocrine Biosciences in a research note on Monday, June 2nd. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a “market perform” rating in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the transaction, the director owned 37,491 shares in the company, valued at approximately $4,131,508.20. This represents a 44.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ingrid Delaet sold 457 shares of the company’s stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares in the company, valued at approximately $638,550. This represents a 8.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 120,251 shares of company stock worth $14,978,602 in the last 90 days. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.